A significant difference in the FLAD1 expression between cancer samples and normal tissue samples was identified for eight cancer types (Figure 2, p < 0.001), including kidney renal papillary cell carcinoma, head-neck squamous cell carcinoma, esophageal cancers, colon adenocarcinoma, cholangiocarcinoma, breast invasive carcinoma, bladder urothelial carcinoma, and liver hepatocellular carcinoma. Here, FLAD1 is linked to esophageal cancer.